Zentalis Pharmaceuticals, Inc. (ZNTL) Stock Price & Analysis
Zentalis Pharmaceuticals, Inc. (ZNTL) fell 2.70% to USD 4.33 as of July 26, 2026 at 11:57 UTC, according to Nexqual real-time market data.
ZNTL last closed at USD 4.45; the session ranged USD 4.17–4.59 on volume of 1,212,586 shares. Market capitalization is $308.24M, with a 52-week range of USD 1.21–6.95 (NGM). Source: Nexqual, July 26, 2026 at 11:57 UTC.
Key Statistics (as of July 26, 2026 at 11:57 UTC)
| Price | USD 4.33 |
|---|---|
| Change | ▼ 2.70% (down) |
| Previous Close | USD 4.45 |
| Open | USD 4.5 |
| Day Range | USD 4.17 – 4.59 |
| 52-Week Range | USD 1.21 – 6.95 |
| Volume | 1,212,586 shares |
| Market Cap | $308.24M |
| Exchange | NGM |
Technical Analysis (ZNTL)
Nexqual's technical model rates ZNTL "BUY" based on 4 bullish and 2 bearish signals across 125 daily candles, as of July 26, 2026 at 11:57 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 47.43 (neutral) |
| vs SMA50 | Above (USD 4.16) |
| MACD | 0.14 (positive) |
Analyst Ratings (ZNTL)
Wall Street analysts rate ZNTL "Buy" based on 9 analysts, with a mean price target of USD 6.67 (range USD 4–10), per Nexqual as of July 26, 2026 at 11:57 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 9 |
| Mean Target | USD 6.67 |
| High Target | USD 10 |
| Low Target | USD 4 |
| Buy / Hold / Sell | 5 / 5 / 0 |
Earnings (ZNTL)
| Next Earnings Date | 2026-08-06 |
|---|---|
| EPS Estimate | USD -0.48 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2025-12-31 | USD -0.49 vs est -0.61 ▲ beat |
| 2025-09-30 | USD -0.37 vs est -0.48 ▲ beat |
| 2025-06-30 | USD -0.37 vs est -0.52 ▲ beat |
Source: Nexqual, July 26, 2026 at 11:57 UTC.
Financials & Fundamentals (ZNTL)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -51.93% |
| Debt / Equity | 21.16 |
| Current Ratio | 6.19 |
| Total Cash | $211.76M |
| Total Debt | $38.65M |
| Free Cash Flow | $-81.38M |
Source: Nexqual, July 26, 2026 at 11:57 UTC.
Financial Health Score (ZNTL)
Nexqual rates Zentalis Pharmaceuticals, Inc.'s overall financial health "Weak" across five dimensions, as of July 26, 2026 at 11:57 UTC.
| Growth | Critical — Revenue -100% YoY (annual), sharp decline |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $212M cash vs $39M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$126M |
| Efficiency | Critical — ROE -52%, ROA -27.9% |
Ownership (ZNTL)
| Insider Ownership | +22.84% |
|---|---|
| Institutional Ownership | +61.92% |
| Shares Outstanding | 71.19M |
| Float | 48.56M |
| Short % of Float | +10.81% |
Source: Nexqual, July 26, 2026 at 11:57 UTC.
Leadership (ZNTL)
Zentalis Pharmaceuticals, Inc. is led by Julie M. Eastland (age 61), CEO, President & Director, per Nexqual as of July 26, 2026 at 11:57 UTC.
| CEO, President & Director | Julie M. Eastland (age 61) |
|---|---|
| Senior Vice President of Commercial Strategy | Sarah Kelly |
Major Backers & Investors (ZNTL)
Notable institutional backers of Zentalis Pharmaceuticals, Inc. include 5AM Venture Management, LLC, Squadron Capital Management LLC, Two Sigma Investments, LP, according to Nexqual as of July 26, 2026 at 11:57 UTC.
Active Investors
| Investor | Stake |
|---|---|
| 5AM Venture Management, LLC | 5.55% |
| Squadron Capital Management LLC | 5.1% |
| Two Sigma Investments, LP | 4.15% |
| Acadian Asset Management. LLC | 4% |
| Renaissance Technologies | 2.72% |
| Citadel | 2.43% |
| Shaw D.E. & Co., Inc. | 2.08% |
| Opaleye Management Inc. | 1.98% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 6.89% |
Source: Nexqual, July 26, 2026 at 11:57 UTC.
From Zentalis Pharmaceuticals, Inc.'s Latest SEC 10-K Filing (filed 2026-03-26)
Key Strengths & Strategy (as disclosed to the SEC)
- In-licensed Patents and Patent Applications Our wholly owned subsidiary, Zeno Management, Inc., or ZMI, has exclusively in-licensed or is the owner/assignee of issued patents and patent applications directed to our technology across our pipeline in the United States and many other major jurisdictions worldwide, including Europe, Japan and China.
- We also rely on know-how and trade secret relating to our proprietary technology and product candidates and continuing innovation to develop, strengthen and maintain our proprietary position.
- Our commercial success will depend in part on our ability to obtain and maintain patent and other proprietary protection for our technology, inventions and improvements; to defend and enforce our proprietary rights, including any patents and trade secrets that we may own in the future; and to operate without infringing the valid and enforceable patents and other proprietary rights of third parties.
- For example, third parties may have blocking patents that could be used to prevent us from commercializing our product candidates and practicing our proprietary technology, and our issued patents may be challenged, invalidated, deemed unenforceable or circumvented, which could limit our ability to stop competitors from marketing-related products or could limit the term of patent protection that otherwise may exist for our product candidates.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| KROS | Keros Therapeutics, Inc. | USD 10.06 | ▼ 1.47% |
| ALXO | ALX Oncology Holdings Inc. | USD 2.03 | ▲ 0.5% |
| ORIC | Oric Pharmaceuticals, Inc. | USD 12.1 | ▲ 12.56% |
| KYMR | Kymera Therapeutics, Inc. | USD 110.57 | ▲ 0.21% |
| RLAY | Relay Therapeutics, Inc. | USD 18.44 | ▼ 4.31% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 26, 2026 at 11:57 UTC. This page is informational and not investment advice.